SHARON HILL, Pa., (October 22, 2015) – Soleo Health, “Soleo,” an innovative leader in specialty infusion, announced today that it has been selected by Bio Products Laboratory (BPL) to dispense Coagadex® (Coagulation Factor X, Human).  On October 20, 2015, Coagadex was approved by the U.S. Food and Drug Administration for the treatment of adults and children (aged 12 years and above) with hereditary factor X deficiency for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with mild hereditary factor X deficiency.

Soleo_Health_News

 

SOLEO HEALTH SELECTED BY BIO PRODUCTS LABORATORY (BPL) TO DISPENSE COAGADEX® 

New Blood Coagulation Factor X (Human), the first and only treatment for hereditary factor X deficiency

SHARON HILL, Pa., (October 22, 2015) – Soleo Health, “Soleo,” an innovative leader in specialty infusion, announced today that it has been selected by Bio Products Laboratory (BPL) to dispense Coagadex® (Coagulation Factor X, Human).  On October 20, 2015, Coagadex was approved by the U.S. Food and Drug Administration for the treatment of adults and children (aged 12 years and above) with hereditary factor X deficiency for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with mild hereditary factor X deficiency.    

Hereditary factor X deficiency is a rare bleeding disorder that affects approximately 300-600 patients in the U.S. Affected individuals often have inadequate amounts of circulating factor X, an important component of the coagulation system. Factor X deficient patients are at increased risk of bleeding and need to be managed similarly to hemophilia patients.

“We are excited to offer patients with hereditary factor X deficiency and prescribing physicians the option of Coagadex as the first and only treatment option specifically developed and approved for this rare condition,” said Craig Vollmer, Executive Vice President of Strategic Development.  “By selecting Soleo Health to dispense this new therapy, BPL recognizes Soleo’s commitment to providing exceptional patient care and services to the bleeding disorders community.”

Like all of Soleo’s proprietary therapy management programs, Coagadex will be managed by a team of experienced clinicians and support personnel.  “Our pharmacists, registered nurses and reimbursement teams have completed extensive training on Coagadex dosing and administration and are prepared to provide treatment and clinical education to patients who make the decision with their physician to infuse Coagadex,“ Vollmer added.

About Bio Products Laboratory

Bio Products Laboratory, Ltd. (BPL) is a leading manufacturer of plasma-derived protein therapies with global headquarters in Elstree, England, US headquarters in Durham, NC, and a presence in more than 45 countries worldwide.  The company has over 60 years of experience developing and manufacturing plasma-derived therapies since being established as part of the Lister Institute in 1950, and currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin.  BPL is committed to continued investment in research and development to maintain its key position as a reliable supplier of high-quality products to patients and healthcare providers worldwide.

About Soleo Health

Soleo Health is an innovative national provider of specialty home and alternate-site infusion services. Its team of experienced clinicians provides exceptional care in managing complex disease states through comprehensive pharmacy, nursing, education, and therapy management programs driven by technology. With a consultative approach to customer service, Soleo ensures patients’ financial, clinical and administrative needs are met by compassionate and caring associates, resulting in greater customer satisfaction.

Soleo Health serves the United States through locations across the country and is accredited by The Joint Commission and URAC. For more information, visit www.soleohealth.com.